`EUROPEANJOURNALOFALLERGY
`l[C ' 0
`
`
`
`
`‘
`
`‘3
`
`AND CLINICAL IMMUNOLOGY
`
`
`
`
`
`
`
`
`
`Allergy‘
`v.70 no 10 (O
`,
`.
`ct. 2015
`General Collection
`W1 AL564
`201540—28 10:44:30
`
`)
`
`Volume 70 - Number 10 0 October 2015
`
`1.37beta-Glucanasa
`
` Thaumatin-like protein
`non defined
`
`
`
`, Superoxid
`
`dismutase
`
`Luminal binding
`protein
`
`lsoflavo
`
`
`a
`reductase (IFR) n Cor
`6
`
`
`Calmodulin
`
`
`X8 domain
`containing
`
`Protein
`
`
`
`methyleslerase
`
`
`
` Plant invenasel
`
`pectin methyl—
`eslerase inhibitor
`
`
`
`
`PROPENAfigfifAHf
`
`LIBRARY or
`MEDICINE
`
`
`
`
`
`Mmm _
`" :fig' M5?
`1»
`
`Page] 0f14
`
`l
`
`.
`
`_ M
`‘
`
`
`a“
`
`
`
`
`,
`
`Official Journal of the European Academy
`This materialwa
`“agglillergy and Clinical Immunology
`atthe NLMarld maybe
`l
`‘
`"s'-
`‘_..--"«
`“"é’fl’n‘
`”inn“! ”n“? '1‘“ A
`-nwu,Wl
`_
`
` L EXHI
`
`
`
`
`
`
`Page 1 of 14
`
`CSL EXHIBIT 1077
`
`

`

` EUROPEAN JOURNAL OF ALLERGY
`
`AND CLINICAL IMMUNOLOGY
`
`
`\r.
`_
`‘
`
`am to. rimmmv u: m . 9 Hr!
`.W i Ltw LAL IMIIIJNUI um
`
`
`
`ASSOCIATE EDITORS
`Werner Aberer, Austria
`Reto Crameri, Switzerland
`Pascal Demoly, France
`Wytske J. Fokkens, the Netherlands
`Angela Haczku, USA
`Antonella Muraro, ltaly
`Bodo Niggemann. Germany
`Douglas 5. Robinson, UK
`Marek Sanak. Poland
`De Yun Wang, Singapore
`Michael Wechsler, USA
`Stephan Weidinger. Germany
`
`EDITORS IN CHIEF
`Professor Thomas Bieber
`Department of Dermatology and Allergy
`University of Bonn
`Sigmund Freud Str. 25
`53105 Bonn
`Germany
`Tel; + 1.9 228 2871 4388
`E-mail: Thomas.Biebertaukb.uni—bonn.de
`Professor Hans-Uwe Simon
`Institute of Pharmacology
`University of Bern
`lnselspital, INO-F
`CH-3010 Bern
`Switzerland
`Tel: + 4131632 3281
`E-mail: hust'dpki.unibe.ch
`
`EDITORIAL BOARD
`Rob Aalberse, the Netherlands
`Miibecell Akdis, Switzerland
`Alaina J. Ammit, Australia
`Andreas Bircher, Sv/itzcrland
`Jochen Brasch, Germany
`Paulo Camargos. Brazil
`Sang-Heon Cho, Korea
`Loren Dentinger, USA
`Jessy Deshane, USA
`Kees van Drunen, the Netherlands
`Philippe Eigenmann, Switzerland
`Thomas Eiwegger, Austria
`Thomas Frischer, Austria
`Johannes Geier, Germany
`Hans Gro‘nlund, Sweden
`Stephan Von Gunten, Switzerland
`Susanne Halken. Denmark
`Karin Hartmann, Germany
`Liam G. Heaney, UK
`Peter Hellings, Belgium
`John Holloway, UK
`Alison Humbtes, USA
`Alan D. Irvine, Ireland
`Michael Kabesch, Germany
`Harsha Kariyawasam, UK
`Thomas Kaufmann, Switzerland
`BIOSTATISTICIANS
`Gerard Koppelman, the Netherlands
`Philippe Bousquet, France
`Susanne Lau, Germany
`Manuel Ferreira, Australia
`Zheng Liu. China
`
`
`Axel Lorentz, Germany
`Marcus Maurer, Germany
`Martin Mempel, Germany
`Gunnar Nilsson, Sweden
`Nathalia Novak, Germany
`Kimihiro Okubo, Japan
`Liam O'Mahony, Switzerland
`Oscar Palomares, Spain
`Gianni Passalacqua, Italy
`Susan Prescott, Australia
`Benjamin Raby, USA
`Claudio Rhyner, Switzerland
`Graham Roberts. UK
`Michaela Schedel, USA
`Jochen Schmitt, Germany
`Jijrgen Schwarze, UK
`Dagmar Simon. Switzerland
`Francois Spertini, Swttzerland
`Jordi Sunyer, Spain
`Bernard Thong, Singapore
`Sanna ToppiIa—Salmi, Finland
`Maria Torres, Spain
`Thomas Werfel, Germany
`Andreas Wollenberg. Germany
`
`Aims and Scope
`Rights Organisation lRROI, e.g. Copyright Clearance Center ICCC]. 222 Rosewood
`Drive, Danvers, MA 01923, USA lwww.copyright.comi, provided the appropriate fee
`The aim of the journal is to promote and maintain contact between basic and clinical
`is paid directly to the RRO. This consent does not extend to other kinds of copying
`allergy and immunology. Allergy is an internationaljournal with contributors and
`readers in all countries. Articles are accepted purely on the basis of quality. The journal
`such as copying for general distribution. for advertising or promotional purposes, for
`creating new collective works or for resale. Special requests should be addressed to
`publishes original articles, reviews, position papers, and briefcommunicatiens, Original
`permissionslfiwiley com.
`articles of special interest are accompanied by editorial comments. Correspondence to
`recently published work is also considered
`ALLERGY, [ISSN 0105-4538], is published monthly. US mailing agent: Mercury Media
`information for subscribers
`Processing, LLC, 1850 Elizabeth Avenue. Suite #C, Rahway, NJ 07065 USA. Periodical
`postage paid at Rahway, NJ.
`Allergy is published in 12 issues per year. Institutional subscription prices for 2015 are:
`Print & Unline: US$2357 IUS], US$2748 [Rest of World], €1785 [Europe], E14041UKI.
`Postmaster: Send all address changes to ALLERGY, John Wiley & Sons inc., C/D The
`Prices are exclusive of tax. Asia-Pacific GST, Canadian CST/HST and European VAT will
`Sheridan Press, PO Box 465, Hanover, PA 17331.
`be applied at the appropriate rates. For more information on current tax rates, please go
`Disclaimer: The Publisher, the European Academy of Allergy and Clinical Immunology
`to www.wileyonlinelibrarycom/tax-vat, The price includes online access to the current
`and all online back files to January 1st 2011, where available. For other pricing options,
`and Editors cannot be held responsible for errors or any consequences arising from the
`including access information and terms and conditions, please visit
`use of information contained in thisjournal, the views and opinions expressed do not
`necessarily reflect those of the Publisher. the European Academy of Allergy and Clinical
`wv.vw.wileyonlinelibrary.com/access,
`Immunology and Editors, neither does the publication of advertisements constitute
`Delivery Terms and Legal Title: Where the subscription price includes print issues and
`any endorsement by the Publisher, the European Academy ofAllergy and Clinical
`delivery is to the recipient's address. delivery terms are Delivered at Place IDAPI; the
`Immunology and Editors of the products advertised.
`recipient is responsible for paying any import duty or taxes. Title to all issues transfers
`FOB our Shipping point, freight prepaid. We will endeavour to fulfil claims for missing or
`Allergy is published by John Wiley & Sons Ltd, PO 00x1354.9600 Garsington Road,
`Oxford OXA 2X6, UK.
`damaged copies within six months of publication. within our reasonable discretion and
`subject to availability.
`View this journal online at wiIeyonlinclibrary.com/journal/all.
`Journal Customer Services: For ordering information, claims and any enquiry
`Allergyaccepts articles for Open Access publication. Please see http://olabout Wiley,
`concerning yourjournal subscription please go to www.wileycustomerhelpcom/ask or
`com/WileyCDA/Section/id-606241.html for further information about OnlineOpen.
`contact your nearest office:
`ISSN 0105-4538 [Print] ISSN 1398-999510nlinei
`Americas: Email: cs-journalsl'dwileycom; Tel: +1 781388 8598 or 1 800 835 6770
`IToll free in the USA 8: Canada).
`Access to thisjournal is available free online within institutions in the developing
`Europe. Middle East and Africa: Email; cs-journalsfflwdeycom; Tel: +46 [0] 1865 778315.
`world through the HINARI initiative with the WHO. For information, visit www.
`Asia Pacific: Email: cs-iournalsfawileycom; Tel; +65 6511 8000.
`healthinternelwork.org
`Japan: For Japanese speaking support, Email: cs-iapanfdwiley.com; Tel: +65 6511 8010
`or Tel [toll-free]: 005 316 50 480.
`Allergy is indexed by Biological Abstracts/BIOSIS, Chemical Abstracts. Current Contents:
`Visit our Online Customer Help available in 7 languages at www.wileycustomerhelpcom/ask
`Clinical Medicine, Elsevier BIOBASE/CurrentAwareness in Biological Sciences,
`EMBASE, index Medicus/M EDLINE. Science Citation index,
`Back issues: Single issues from current and recent volumes are available at the current
`single issue price from cs-journalsiawileycom. Earlier issues may be obtained from
`Wiley's Corporate Citizenship initiative seeks to address the environmental, social,
`Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA.
`economic, and ethical challenges faced in our business and which are important to our
`Tel: +1 518 537 4700, Fax: +1 518 537 5899, Email: pscfaperiodicalscom
`diverse stakeholder groups. Since launching the initiative, we have focused on sharing
`our content with those in need, enhancing community philanthropy. reducing our
`Production Editor: Emily Sanchez Iemail: allfdwileycom].
`carbon impact, creating global guidelines and best practices for paper use, establishing
`Copyright and copying
`a vendor code of ethics, and engaging our colleagues and other stakeholders in our
`efforts. Follow our progress at www.wiley.com/go/citizenship.
`Copyright © 2015 John Wiley & Sons A/S. Published by John Wiley 8: Sons Ltd, All
`rights reserved. No part of this publication may be reproduced, stored or transmitted
`For submission instructions, subscription and all other information visit: onlinelibrary.
`in any form or by any means without the prior permission in writing from the copyright
`wiley.com/journal/10.1111/IISSNI1378—‘7995
`holder. Authorization to copy items for internal and personal use is granted by the
`Printed in Singapore by (2.0.5. Printers Pte Ltd.
`copyright holder for libraries and other users registered with their local Reproduction
`
`
`The cover image depicts: Molecular characterization of tree pollen allergens. From Asam C, Hofer H. Wolf M, Aglas L, Wallner M. Tree pollen allergens—an
`update from a molecular perspective. Allergy 2015; 70: 1201-1211.
`
`Page 2 of 14
`
`This material was compiled
`atthe NLIvI and may be
`Subject: US Copyright Laws
`
`Page 2 of 14
`
`

`

`0/0 $00;
`’0 oral/50
`2%, O/Ib 0%,.
`4% G 0%,
`49% (’6
`0,7)
`9»
`
`’'
`
` ’/
`
`EUROPEAN JOURNAL OF ALLERGY
`AND CLINICAL IMMUNOLOGY
`
`CONTENTS
`
`Volume 70 - Number 10 - October 2015
`
`NEWS AND
`COMMENTARIES
`
`1193 Consensus communication on early peanut introduction and the prevention
`of peanut allergy in high-risk infants
`primaryContributors:, D. M. Fleischer, S. Sicherer, M. Greenhawt, D. Campbell,
`E. Chan, A. Muraro, S. Halken, Y. Katz, M. Ebisawa, L. Eicnen, H. Sampson, H. Sampson,
`G. Lack, G. DU TOit, G. Roberts, H. Bahnson, M. Feeney, J. Hourihane, J. Spergel,
`M. Young, A. As'aad, K. Allen. S. Prescott, S. Kapur, H. Saito, |. Agache. C. A. Akdis.
`H. Arshad, K. Beyer, A. Dubois, P. Eigenmann, M. Fernandez—Rivas, K. Grimshaw,
`K. Hoffman—Sommergruber, A. Host, S. Lau, L. O'Mahony, C. Mills, N. Papadopoulos,
`C. Venter, N. Agmon-Levin, A. Kessel, R. Antaya, B. Drolet and L. Rosenwasser
`
`REVIEW ARTICLES
`
`1196 Angioedema induced by cardiovascular drugs: new players join old friends
`M. Bas, J. Greve, U. Strassen, F. Khosravani, T. K. Hoffmann and G. Kojda
`
`1201 Tree pollen—allergens an update from a molecular perspective
`C. Asam. H. HOfer. M. Wolf, L. Aglas and M. Wallner
`
`POSITION PAPER
`
`1212 Pathophysiological mechanisms of exercise-induced anaphylaxis: an EAACI
`position statement
`L. Ansley, M. Bonini, L. Delgado, 8. Del Giacco. G. Du Toit, M. Khaitov, M. Kurowski,
`J. H. Hull, A. Moreira and P. J. Robson—Ansley
`
`ORIGINAL ARTICLES
`
`Experimental Allergy And Immunology
`
`1222 Poor association of allergen-specific antibody, T- and B-cell responses
`revealed with recombinant allergens and a CFSE dilution-based assay
`J. Eckl-Dorna. R. Campana. R. Valenta and V. Niederberger
`
`1230 Urinary 11B-PGF20L and N-methyl histamine correlate with bone marrow
`biopsy findings in mast cell disorders
`R. Divekar and J. Butterfield
`
`1239 Ara h 2 and Ara 6 are the best predictors of severe peanut allergy: a
`double-blind placebo-controlled study
`A. K. KUkkonen, A. S. Pelkonen, S. Makinen—Kiljunen. H. VOUtilainen and M. J. Makela
`
`1246 Allergic sensitization is associated with inadequate antioxidant responses in
`mice and men
`
`L. Utsch, C. Folisi, J. H. Akkerdaas, A. Logiantara, M. A. Van De Pol, J. S. Van Der Zee,
`E. J. M. Krop, R. Lutter, R. Van Ree and L. S. Van Rijt
`
`1259 MPLA shows attenuated pro-inflammatory properties and diminished capacity
`to activate mast cells in comparison with LPS
`S. SchUlke, A. Flaczyk. L. Vogel, N. Gaudenzio, l. Angers, B. LO‘schner, S. Wolfheimer,
`I. Spreitzer‘, S. Qureshi, M. Tsai, S. Galli, S. Vieths and S. Scheurer
`
`1269 Intrinsic properties of germinal center-derived B cells promote their enhanced
`class switching to lgE
`F. Ramadani, N. Upton, P. Hobson, Y.— C. Chan, D. Mzinza, H. Bowen, C. Kerridge,
`B. J. Sutton, D. miFwM—Ifid‘HfifiJfl-fiiedld
`at the NLM and may be
`Subject J3 {logyright Laws
`
`Page 3 of 14
`
`Page 3 of 14
`
`

`

`1278
`
`1288
`
`1300
`
`1309
`
`1319
`
`1329
`
`1332
`
`1 336
`
`1 340
`
`1346
`
`1350
`
`1352
`
`Farm exposures are associated with lower percentage of circulating myeloid
`dendritic cell subtype 2 at age 6
`M.- V. Martikainen, H. Kaério, A. Karvonen, P. C, Schr‘dder, H. Renz, V. Kaulek,
`J.— C. Datphin. E. Von Mutius, B. Schaub, J. Pekkanen, M.- R. Hirvonen and M. Roponen
`
`Epidemiology And Genetics
`
`Childhood asthma is associated with mutations and gene expression
`differences of ORMDL genes that can interact
`A. A. Toncheva, D. P. Potaczek, M. Schedel, S. W. Gersting, 5. Michel, N. Krajnov,
`V. D. Gaertner, J. M. Klingbeil, T. Illig, A. Franke, C. Winkler, J. M. HohlfeLd, C. Vogelberg,
`A. Von berg. A. Bufe, A. Heinzmann, 0. Laub, E. Rietschel, B. Simma. J. Genuneit,
`A. C. Muntau and M. Kabesch
`
`Association between adult atopic dermatitis, cardiovascular disease, and
`increased heart attacks in three population-based studies
`J. |. Silverberg
`
`Airway Diseases
`
`eQTL of bronchial epithelial cells and bronchial alveolar lavage deciphers
`GWAS-identitied asthma genes
`X. Li, A. T. Hastie, G. A. Hawkins, W. C. Moore, E. J. Ampleford, J. Milosevic, H. Li,
`W. W. Busse, S. C. Erzurum, N. Kaminski, S. E. Wenzel, D. A. Meyers and E. R. Bleecker
`
`Immunodeficiencies
`
`Phase II study results of a replacement therapy for hereditary angioedema
`with subcutaneous C1-inhibitor concentrate
`
`B, L. Zuraw, M. Cicardi, H. J. Longhurst, J. A. Bernstein, H. H. Li, M. Magerl, |. Martinez—
`Saguer, S. M. M. Rehman, P. Staubach, H. Feuersenger, R. Parasrampuria, J. Sidhu,
`J. EdeLman and T. Craig
`
`Diagnostic test allergens used for in viva diagnosis of allergic diseases are at
`risk: a European Perspective
`L. Klimek, H. J. Hoffmann, H. Renz, P. Demoly, T. Werfel, P. M. Matricardi, A. Muraro,
`P. Schmid-Grendelmeier, V. Cardona and N. G. Papadopoulos
`
`Diagnostic use of recombinant Tha p 2 in the allergy to Thaumetopoea
`pityocampa
`A.
`|. Rodriguez—Mahillo, N. Carballeda-Sangiao, J. M. Vega, J. C. Garcia-Ortiz, A. Roques,
`i. Moneo and M. Gonzalez-Munoz
`
`T helper 2 response in allergic bronchopulmonary aspergillosis is not driven
`by specific Aspergillus antigens
`H. Jolink, R. de Boer, L. N. A. Willems, J. T. van Dissel, J. H. F. Falkenburg and
`M. H. M. Heemskerk
`
`Bee venom enhances the differentiation of human regulatory T cells
`I. Caramalho, A. Melo, E. Pedro, M. M. P. Barbosa, R. M. M. Victorino, M. C. Pereira Santos
`and A. E. Sousa
`
`Prevalence of celiac disease in patients with severe food allergy
`R. Pillon, F. Ziberna, L. Badina. A. Ventura, G. Longo, S. Ouaglia, L. De Leo, S. Vatta,
`S. Martelossi, G. Patano, T. Not and |. Berti
`
`The influence of childhood traffic-related air pollution exposure on asthma,
`allergy and sensitization
`E. Fuertes and J. Heinrich
`This mate-rial was-{Upied
`atthe NLMand may he
`Subject USEiopyright Laws
`
`Reply
`
`
`
`BRIEF
`
`COMMUNICATIONS
`
`CORRESPONDENCE
`
`Page 4 of 14
`
`Page 4 of 14
`
`

`

`
`
`concentrate
`
`B. L. Zuraw1, M. Cicardiz, H. J. Longhurst3, J. A. Bernstein‘, H. H. Li5, M. Magerle, |. Martinez-8a uer7,
`S. M. Mafiehmans, P. Staubachg, H. Feuersengerw, R. Parasrampuria”, J. Sidhun, J. Edelman1 &
`T. Craig
`
`1Department of Med:cine, University of California, San Diego, La Jolla, CA, USA; 2Department of internal Medicine, Universita degli Studi di
`Milano, Ospedale L. Sacco, Milan, ltaiy; 3Department of Immunology, Barts Health NHS Trust, London, UK; “Department of Imrnunology/
`Allergy, University of Cincinnati College of Medicine, Cincinnati, OH; 5institute for Asthma and Allergy, Chevy Chase, MD, USA; 6Charité,
`Universitétsmedizin Berlin, Berlin; 7HZRM Haemophilia Centre Rhine Main, Mdrfelden—Walldorf, Germany: 8Toledo institute Asthma and Allergy
`Center, Toledo, OH, USA; 9University Medical Center, Mainz; 10CSL Behring GmbH, Marburg, Germany; HCSL Behring, King of Prussia, PA.
`USA; 12CSL Limited, Parkville, Vic., Australia; IaDepartments of Medicine and Pediatrics, Penn State University, Hershey, PA. USA
`
`To cite this article: Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, Martinczesaguer I, Rehman SMM, Staubach P, Feuersenger H,
`Parasrampuria Ft, Sidhu J, Edelman J, Craig T. Phase II study results of a replacement
`therapy for hereditary angioedema with subcutaneous Ci—inhibitor
`concentrate. Allergy 20l5; 70: 131971328.
`
`
`
`Abstract
`
`Keywords
`Berincrt; Ci—esterase inhibitor; hereditary
`inhibitor dehctcncy
`(HAE) due to C1
`angioedema; long—term prophylaxis; subcuta— Background: Hereditary angioedema
`neous treatment.
`manifests as recurrent swelling attacks that can be disabling and sometimes fatal.
`Long‘term prophylaxis with twice-weekly intravenous injections of plasma-derived
`Cl-inhibitor (pdCl-INH) has been established as an effective treatment. Subcutane-
`ous (SC) administration ot‘pdCl-INH has not been studied in patients with HAE.
`Methods: This open-label, dose—ranging, crossover study (COMPACT Phase II) was
`conducted in 18 patients with type I or II HAE who received two ot‘twice-weekly 1500,
`3000, or 6000 IU SC doses of highly concentrated volume-reduced CSL830 for 4 weeks
`each. The mean trough plasma levels of Cl-INH functional activity, Cl-INH and C4
`antigen levels during Week 4, and overall safety and tolerability were evaluated. The
`primary outcome was model-derived steadystate trough Cl—INH functional activity.
`Results: After SC CSL830 administration, a dose-dependent increase in trough func-
`,
`,
`,
`,
`‘
`menu] Cl-INH actiVity was observed. Ci-INH and C4 levels both increased. "the
`two highest dose groups (3000 and 6000 IU) achieved constant Cl—INH activity lev-
`els above 40% values, a threshold that was assumed to provide clinical protection
`against angioedema attacks. Compared with intravenous injection, pdCl-INH SC
`injection with CSL830 showed a lower pcak-to-trough ratio and more consistent
`exposures. All doses were well tolerated. Mild-to-modcrate local site reactions were
`noted with pain and swelling being the most common adverse event.
`Conclusions: Subcutaneous volume-reduced CSL830 was well tolerated and led to
`a dose—dependent increase in physiologically relevant functional Cl-INH plasma
`levels. A clinical otitcomc study of SC CSL830 in patients with HAE warrants
`further investigation.
`
`Abbreviations
`
`correspondence
`Bruce L. Zuraw, MD, Department of Medi-
`cine, University of California, San Diego,
`9500 Gilman Dr., Mail Code 0732. La Jolla,
`CA 92093-0733 USA
`Tel.: +1 858 822 6597
`Fax: +1 858 642 379i
`E-mail: bzuraw@uesd,edu
`
`ClinicalTrials. ov identifier: NCT01576523.
`9
`Accepted for publication 22 May 2015
`
`DQ|;10,1111/a]r12558
`
`Edited by; Werner Aberer
`
`AE, adverse event; AUCw ,,, area under the plasma concentrationetime curve over a dosing interval; Ct-INH, Ct»inhibitor; CW, average Cl-
`iNH functional activity over dosing interval; CI, confidence interval; CL. clearance; CLss, steady—state clearance; Cmax, maximum drug
`concentration in plasma; CSL830, volume-reduced C1-lNH concentrate; F, bioavailability; HAE, hereditary angioedema due to Cl
`inhibitor
`deficiency; IU, international unit; lV, intravenous; Ka, absorption rate constant; kDa, kiloDalton; pd, plasma-derived; PD, pharmacodynamicc
`PK, pharmacokinetic; pnf, pasteurized, nanofiltered; SC, subcutaneous; SD, standard deviation; t1/2. half-life; TEAE, treatment-emergent
`adverse event; U, unit; V, volume of distribution; V55, steady-state volume of distribution; WT, body weight.
`
`Allergy 70 (2015) 1319—1328 © 2015 The Authors. Allergy Published by John Wiley & Sons Ltd,
`This is an open access article under the terms of the Creative Commons AttributionrNonCornmercialNcDorivs License, which permits use and
`distribution in any medium, provided the original work is properly cited, thfiigsfiéstgogcmegiagfld no modifications or adaptations are made.
`at the FILM and may be
`Subject Uiflopyright Laws
`
`1319
`
`Page 5 of 14
`
`Page 5 of 14
`
`

`

`
`
`Subcutaneous C1-INH replacement for HAE
`
`Zuraw et al.
`
`Hereditary angioedema (HAE) is a rare autosomal dominant
`disease caused by C1 inhibitor deficiency and is associated
`with significant morbidity and mortality (14), which has been
`substantially reduced with the advent of effective on-demand
`therapies (5). However, patients continue to have impaired
`quality of life and in seine cases require hospitalization for an-
`gioedema attacks. To minimize the number and severity of
`attacks, many patients choose to use prophylactic treatment,
`Consensus guidelines conclude that long-term prophylaxis is
`appropriate for HAE patients with frequent attacks or who do
`not achieve suftieient benefit from Oil-demand treatment (4, 6e
`1 1). Before 2009, the most commonly utilized prophylactic drugs
`were anabolic androgens and to a lesser extent antifibrinolytics,
`Subsequently, long-term prophylaxis with Cl inhibitor concen—
`trates (Cl-INH) has become available and found to be safe and
`effective (12). The concept of routine prophylaxis with continu-
`ous intravenous Cl-lNH is based on correcting the deficiency of
`Cl-INH activity,
`the fundamental abnormality in HAE. The
`efficacy of this approach was shown in two placebo—controlled
`studies;
`the efficacy of a vapor-heated Cl-INH concentrate
`(25 U/kg body weight) was established for long-term prophy-
`laxis in patients who did not respond adequately to androgcns
`or antifibrinolytics (13), and the Cl-INH concentrate (Cinryzc,
`1000 IU twice a week) demonstrated a reduction in the number
`of HAE attacks (12). However, none of the previous studies on
`CI-INH replacement
`therapy were specifically designed to
`achieve a constant level of biologically relevant activity Cl-INII
`levels. Thus, most patients on intravenous Cl-lNH long-term
`prophylaxis continue to experience breakthrough attacks, likely
`related to the relatively short period of time that functional
`Cl-INH plasma levels remain near the normal range (13).
`levels
`Theoretically, maintaining plasma Cl-INH functional
`above a certain threshold should prevent all attacks. However,
`this threshold value has not yet been defined. Hereditary angioe—
`dema is diagnosed based on functional Cl-lNH levels <50% of
`normal, but patients typically have Cl-INH functional
`levels
`<40% of normal (14, 15). Enhanced activation of the complement
`system has been observed with Cl-INH functional levels <38%
`of normal, suggesting a critical
`threshold of Cl-INH function
`(16). Logistical and technical problems of repeated intravenous
`(IV) injections and the pharmacokinetic (PK) profile make it chal-
`lenging to maintain the Cl—IN H level above a threshold value.
`Subcutaneous (SC) administration of Cl-INH offers sev-
`eral potential advantages including easier access for self-
`administration and more consistent I’Ks. The feasibility of
`SC administration of an IV Cl-INH concentrate (1000 [U in
`20 ml) was previously demonstrated in a pilot study in
`patients with HAE (l7). Herein, the PK, pharmacodynamic
`(PD), and preliminary safety of an investigational, volume-
`reduced Cl-INH concentrate (CSL830; CSL Behring, Mar-
`burg, Germany) developed for SC injection is reported.
`
`Methods
`
`Study medication
`
`CSL830 is a volume-reduced formulation of the pasteurized,
`nanofiltered Cl—INH concentrate (pnf Cl-INH; Berinert‘”,
`
`Marburg, Germany). The manufacturing process of CSL830
`is almost identical to that of pnf Cl-INH, the major differ—
`ence being the concentration after reconstitution. The final
`concentration of CSL830 is 500 lU/ml, whereas the final con—
`centration of Berincrt is 50 IU/ml.
`
`Study design
`
`This was a prospective, multicentcr, open-label, crossover
`phase II study to characterize the PK5, PBS, and safety of
`CSL830 administered subcutaneously to 18 subjects with
`HAE (COMPACT phase 11 study). The study period spanned
`April 2012 to December 2012. Data were collected at three
`sites in Germany and five in the USA. For organizational
`details of the study setup, please refer to the Appendix 81.
`Following a screening period of up to 30 days, subjects
`were sequentially allocated to one of six CSL830 treatment
`sequences by predetermined computer-generated assignment
`(Fig. 1A). A single dose of Berincrt 20 U/kg was adminis-
`tered 1V 2—7 days prior to the first CSLXBO dosing period.
`Each subject received two of three possible CSL830 doses
`(1500, 3000, or 6000 IU administered as a short SC injection
`twice-weekly) for two 4-week treatment periods with a wash-
`out period of up to 4 weeks between periods. Administration
`of rescue medication (IV Cl-lNH) was permitted for break-
`through attacks.
`The study protocol and all amendments were approved by
`the independent ethics committees of the participating sites.
`The study was carried out in accordance with the principles
`of the current International Conference on Harmonization
`Good Clinical Practice.
`
`Study population
`
`Male or female subjects aged 218 with HAE with type I or
`type II HAE, based on clinical history and confirmed by cen-
`tral laboratory testing at screening (Cl-lNH functional activ-
`ity <50% or a Cl-INH antigen level below the laboratory
`reference range), were eligible for the study. Subjects were
`required to have a body weight 250 and 5110 kg at screening
`and have experienced $5 HAE attacks within the 3 months
`prior to the screening visit, of which 51 occurred within
`30 days prior to the screening visit. The relatively low attack
`rate for the inclusion criteria was chosen to minimize the
`need for
`rescue therapy with Cl-lNH concentrate which
`would interfere with the PK measurements.
`
`Key exclusion criteria included current Cl—INH prophylac-
`tic therapy, androgen therapy within 30 days of screening,
`and any HAE-specific treatment within 7 days of screening
`(for full inclusion and exclusion criteria, see Appendix SI).
`
`Endpoints
`
`The primary endpoint was the mean trough Cl-INH func-
`tional activity at
`the fourth week, based on modeling and
`simulation. Model-derived rather than observed trough levels
`were chosen to account for the confounding nature of possi-
`ble rescue IV Cl-lNH use during the study.
`
`1320
`
`Allergy 70 (2015) 13194328 © 2015 The Authors. Allergy Published by John Wiley & Sons Ltd.
`
`Page 6 of 14
`
`Th is material was copied
`at the NLM and may be
`Su bjert. US «item: right Laws
`
`Page 6 of 14
`
`

`

`Zuraw ct al.
`
`Subcutaneous C1-INH replacement for HAE
`
`CSL830 Treatment period
`Dosing period 2
`Dosing period 1
`Se- uence A
`
`
`1500 IU 2x perweek
`
`
`
`3000 IU 2x perweek
`
`3000 IU2—[3—week
`
`
`
`
`3000 IU2xper
`
`
`_000IU2x—erweek
`Single IV
`dose of
`
`A
`
`
`
`.
`
`
`
`
`
`
`subjects
`
`20 IUIkg
`
`
`ll_500l02xperweek.l_000lU2xperweekI
`
`
`6000 IU 2x perweek
`
`1500 IU 2x perweek
`
`
`
`
`
`L-w—JH—’
`
`Within 30 days of
`Dosing Period 1
`(1 visit)
`
`2 to 7 days before
`Dosing Period 1
`(3 visits)
`
`Iv c1-INH
`
`CSL830 administration
`
`4 weeks
`(13 visits)
`
`Up to 4
`weeks
`
`4 weeks
`(13 visits)
`
`1 week
`(1 visit)
`
`| I
`I I
`I
`I
`I
`I
`I
`I
`I
`I
`I
`I
`I
`I
` W
`‘...,.
`(,I,
`IIIIIIII
`I
`IIIIIIII
`I
`I
`IIIIIIII
`
`I
`
`I
`
`I
`
`I
`
`Plasma Ct-INH functional activity and C1-lNHIC4 antigen level assessment
`
`Figure 1 Study schema (A) Dosing scheme and sample collection
`during the study,
`(B) I = single dose of IV Ci-INH;1- single dose
`of subcutaneous (SC) CSL830; I= assessment of Ct-INH func-
`
`Thc secondary endpoints were the mean and mean change
`from baseline in trough Cl-lNH functional activity, Cl-lNl—l
`antigen level, and C4 antigen levels at
`the fourth week of
`each dosing regimen, based on observed data.
`The dosing scheme and sample collection is illustrated in
`Fig. 18. The initial single IV dose of Cl-INH was adminis-
`tcrcd to aid the PK model in accounting for any administra-
`tion of IV Cl-INH rescue doses and to enable a within-study
`estimate of bioavailability of SC CSL830. Cl—INl-l functional
`activity, Cl-lNH plasma concentrations, and C4 antigen lev-
`els were assessed at several time points throughout each dos-
`ing
`period.
`Plasma Cl-INH functional
`activity was
`additionally assessed immediately before CSL830 administra-
`tion.
`
`PK and PD measurements
`
`Plasma Cl-INH functional activity was assessed by a vali-
`dated chromogenic assay (Berichrom Cl-lnltibitor, Siemens;
`
`tional activity and plasma C1-lNH and C4 antigen concentrations:
`I = additional assessments of plasma C1-INH functional activity,
`
`reference range: 70-1300/0 of norm). Plasma Cl-INH antigen
`(Cl
`reagent N-Antisera; Siemens Healtheare Diagnostics
`(Eschbom, Germany); reference range: 0.187032 mg/l) and
`C4 antigen levels were assessed by nephelometry (C4 reagent,
`Beekman Coultcr (Krefeld, Germany); reference range: 0.1—
`0.4 g/l). All measurements were performed at a central labo-
`ratory using a validated assay (CSL Behring GmbH).
`C4 antigen levels were defined as a PD parameter as C4
`activity occurs downstream from Cl—INH; Cl-lNH replace-
`ment would therefore affect C4 levels. Levels of C4 antigen
`have been shown to rise slowly over time following IV pdCl—
`lNll administration.
`
`PK and PD analysis
`
`The complete analysis set (18 patients who received 21 dose
`of CSL830 and provided _>_1 Cl-INH functional measure-
`ment) was used for the primary endpoint analysis and to
`determine modeling-derived Cl—INH functional
`activity.
`
`Allergy 70 (2015) 1319—1328 © 2015 The Authors. A/(ergy Published by John Wiley Ex Sons Ltd.
`
`1321
`
`Page 7 of 14
`
`Th is material was-{sowed
`at the NLM and maybe
`Subject USCopyright Laws
`
`Page 7 of 14
`
`

`

`Subcutaneous C1-INH replacement for HAE
`
`Zuraw et al.
`
`Twelve subjects per dosing regimen were sufficient to provide
`an estimate of Cl-INII activity, based on PK modeling of
`previous study results. The data for each treatment were
`summarized using descriptive statistics and a mixed mode].
`Subcutaneous and IV Cl—INH functional activity data
`were collectively subjected to a population-based approach
`using nonlinear mixed-effects modeling (NONMEM version
`7.2). Exploratory PK characteristics of CSL830 were assessed
`by estimating typical and individual values for parameters
`such as clearance (CL) and volume of distribution (V) along
`with associated interindividual variability. The influence of
`Subject baseline characteristics was also investigated. Pharma-
`cokinetic parameters such as CL, V, bioavailability (F),
`absorption rate constant (K,,), half-life (11/2), and incremental
`recovery were estimated with the final population PK model.
`I’harrmrcokinetic simulations were conducted to examine
`whether steady-state trough levels of Cl-INH functional
`activity were dependent on body weight. The body weight
`effect was evaluated by examining the distributions of model-
`predietcd steady-state trough serum Cl-INH functional activ-
`ity at doses of 40 and 60 IU/kg and fixed doses of 3000 and
`45001U, for baseline body weight ranges of <60, 607100,
`and >100 kg. For the as-observed endpoint analysis,
`the
`fourth-week trough levels and increase in trough levels from
`baseline were summarized for Cl-INH functional activity,
`Cl-INH antigen levels, and C4 antigen levels
`for each
`CSL830 dosing regimen using descriptive statistics.
`
`Safety assessment
`
`Safety and tolerability were evaluated by continuous observa-
`tion of adverse events (ABS) and by safety assessments that
`were conducted at
`specified times
`throughout
`the study.
`These assessments included infusion Site tolerability, labora-
`tory parameters, vital signs, body weight, physical examina-
`tion, and concomitant medication usage. Local side-effects
`(pain, swelling, bruising, and itching at
`the injection site)
`were assessed by the investigator and intensity graded from
`mild (grade 1: present, but no interference with activity) to
`severe (grade 3: prevents daily activity and/or requires Lise of
`pain relievers). A risk assessment for deep vein thrombosis
`was also implemented based on earlier case reports on side-
`effccts of thromboembolism in patients with HAE using
`Cl-INH concentrate (18, 19).
`
`Results
`
`Study subjects
`
`A total of 22 subjects from eight study sites signed the
`informed consent. Of these,
`18 patients were assigned to
`treatment by a computer-generated list and received study
`drug. Four subjects signed the consent form but were not
`randomized,
`two because they did not meet
`the inclusion/
`exclusion criteria and two because the study had already
`reached the target of 18 subjects by the time they were found
`to be eligible. The demographics of the subjects are summa-
`rized in Table 1.
`
`PK results after SC CSL830
`
`The mean as—observed steady—state trough Cl-INH functional
`activity at
`the fourth week increased with CSL830 dose
`(Fig. 2);
`increase from baseline was 16.4%, 33.2%, and
`63.3% for the 1500, 3000, and 6000 IU doses, respectively.
`Cl-INH antigen levels also increased with CSL830 dose;
`increase from baseline in Cl—lNI—I antigen at the fourth week
`was 0.02, 0.05,